0001193125-22-153506.txt : 20220518 0001193125-22-153506.hdr.sgml : 20220518 20220518063400 ACCESSION NUMBER: 0001193125-22-153506 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220518 FILED AS OF DATE: 20220518 DATE AS OF CHANGE: 20220518 FILER: COMPANY DATA: COMPANY CONFORMED NAME: I-Mab CENTRAL INDEX KEY: 0001778016 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39173 FILM NUMBER: 22936997 BUSINESS ADDRESS: STREET 1: 55TH-56TH FLOOR, NEW BUND CENTER STREET 2: 555 WEST HAIYANG ROAD, PUDONG DISTRICT CITY: SHANGHAI STATE: F4 ZIP: 200124 BUSINESS PHONE: 862160578000 MAIL ADDRESS: STREET 1: 55TH-56TH FLOOR, NEW BUND CENTER STREET 2: 555 WEST HAIYANG ROAD, PUDONG DISTRICT CITY: SHANGHAI STATE: F4 ZIP: 200124 6-K 1 d364131d6k.htm FORM 6-K Form 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2022

Commission File Number: 001-39173

 

 

I-MAB

 

 

55th – 56th Floor, New Bund Center, 555 West Haiyang Road, Pudong District

Shanghai, 200124

People’s Republic of China

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F   ☒              Form 40-F   ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

I-MAB Published First ESG Report

I-Mab (“I-Mab” or the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company published its first Environment, Social and Governance Report (the “ESG Report”) on May 18, 2022. The ESG Report can be accessed on the Company’s investor relations website at ir.i-mabbiopharma.com.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

I-MAB
By   :  

/s/ John Long

Name   :   John Long
Title   :   Director and Chief Financial Officer

Date: May 18, 2022